4.7 Editorial Material

Occupy EGFR

Journal

CANCER DISCOVERY
Volume 2, Issue 5, Pages 398-400

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-12-0144

Keywords

-

Categories

Funding

  1. NCI NIH HHS [R01 CA079992, R01 CA079992-14] Funding Source: Medline
  2. NIGMS NIH HHS [R01 GM099891, R01 GM099891-01] Funding Source: Medline

Ask authors/readers for more resources

Erlotinib and gefitinib inhibit the growth of non-small cell lung cancer tumors that harbor activating epidermal growth factor receptor (EGFR) mutations but are ineffective against EGFR variants found in glioblastoma. New studies by Barkovich and colleagues and Vivanco and colleagues show that these drugs only occupy the active sites of glioblastoma-derived EGFR mutants to a limited extent and fail to inhibit the activated receptor. Other EGFR inhibitors that target distinct receptor conformations are more effective in the treatment of glioblastoma. These studies reveal distinct drug selectivities for different EGFR mutations and show that an analysis of binding-site occupancy should be considered as a biomarker for inhibitor efficacy in targeting EGFR. Cancer Discov; 2(5); 398-400. (c) 2012 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Cell Biology

Non-acylated Wnts Can Promote Signaling

Kelsey F. Speer, Anselm Sommer, Benjamin Tajer, Mary C. Mullins, Peter S. Klein, Mark A. Lemmon

CELL REPORTS (2019)

Review Biochemistry & Molecular Biology

Computational algorithms for in silico profiling of activating mutations in cancer

E. Joseph Jordan, Keshav Patil, Krishna Suresh, Jin H. Park, Yael P. Mosse, Mark A. Lemmon, Ravi Radhakrishnan

CELLULAR AND MOLECULAR LIFE SCIENCES (2019)

Article Oncology

Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma

Marta Baro, Cecilia Lopez Sambrooks, Barbara A. Burtness, Mark A. Lemmon, Joseph N. Contessa

MOLECULAR CANCER THERAPEUTICS (2019)

Article Oncology

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

Jacqueline H. Starrett, Alexis A. Guernet, Maria Emanuela Cuomo, Kamrine E. Poels, Iris K. van Alderwerelt van Rosenburgh, Amy Nagelberg, Dylan Farnsworth, Kristin S. Price, Hina Khan, Kumar Dilip Ashtekar, Mmaserame Gaefele, Deborah Ayeni, Tyler F. Stewart, Alexandra Kuhlmann, Susan M. Kaech, Arun M. Unni, Robert Homer, William W. Lockwood, Franziska Michor, Sarah B. Goldberg, Mark A. Lemmon, Paul D. Smith, Darren A. E. Cross, Katerina Politi

CANCER RESEARCH (2020)

Review Biochemistry & Molecular Biology

Insulin and epidermal growth factor receptor family members share parallel activation mechanisms

Kathryn M. Ferguson, Chun Hu, Mark A. Lemmon

PROTEIN SCIENCE (2020)

Article Biochemistry & Molecular Biology

Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases

Joshua B. Sheetz, Sebastian Mathea, Hanna Karvonen, Ketan Malhotra, Deep Chatterjee, Wilhelmiina Niininen, Robert Perttila, Franziska Preuss, Krishna Suresh, Steven E. Stayrook, Yuko Tsutsui, Ravi Radhakrishnan, Daniela Ungureanu, Stefan Knapp, Mark A. Lemmon

MOLECULAR CELL (2020)

Review Biochemistry & Molecular Biology

Comparison of tyrosine kinase domain properties for the neurotrophin receptors TrkA and TrkB

Stephen C. Artim, Anatoly Kiyatkin, Mark A. Lemmon

BIOCHEMICAL JOURNAL (2020)

Article Biochemistry & Molecular Biology

Kinetics of receptor tyrosine kinase activation define ERK signaling dynamics

Anatoly Kiyatkin, Iris K. van Alderwerelt van Rosenburgh, Daryl E. Klein, Mark A. Lemmon

SCIENCE SIGNALING (2020)

Article Multidisciplinary Sciences

EComputational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation

Keshav Patil, Earl Joseph Jordan, Jin H. Park, Krishna Suresh, Courtney M. Smith, Abigail A. Lemmon, Yael P. Mosse, Mark A. Lemmon, Ravi Radhakrishnan

Summary: Kinases are crucial in various cellular processes and commonly mutated in cancer, their activation status can be effectively predicted through computational studies despite mutations occurring throughout the kinase domain. The results provide insights into convergent activation mechanisms in majority of studied mutations.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Article Biochemistry & Molecular Biology

Phosphatidylserine binding directly regulates TIM-3 function

Courtney M. Smith, Alice Li, Nithya Krishnamurthy, Mark A. Lemmon

Summary: This study demonstrates that TIM-3 promotes NF-Kappa B signaling and IL-2 secretion in T cells through binding to phosphatidylserine (PS). The findings clarify the importance of PS as a functional ligand for TIM-3 and suggest that TIM-3 signaling can be regulated by mutating the PS-binding site or occluding it with an antibody.

BIOCHEMICAL JOURNAL (2021)

Article Multidisciplinary Sciences

Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias

Chun Hu, Carlos A. Leche, Anatoly Kiyatkin, Zhaolong Yu, Steven E. Stayrook, Kathryn M. Ferguson, Mark A. Lemmon

Summary: The epidermal growth factor receptor (EGFR) frequently mutates in human cancer, and is an important therapeutic target. However, EGFR inhibitors have limited effectiveness in glioblastoma multiforme (GBM) due to exclusive mutations in the extracellular region. This study reveals that GBM mutations impair EGFR's ability to distinguish between activating ligands, which may have implications for therapeutic targeting.

NATURE (2022)

Article Multidisciplinary Sciences

Structural basis for ligand reception by anaplastic lymphoma kinase

Tongqing Li, Steven E. Stayrook, Yuko Tsutsui, Jianan Zhang, Yueyue Wang, Hengyi Li, Andrew Proffitt, Stefan G. Krimmer, Mansoor Ahmed, Olivia Belliveau, Ian X. Walker, Krishna C. Mudumbi, Yoshihisa Suzuki, Irit Lax, Diego Alvarado, Mark A. Lemmon, Joseph Schlessinger, Daryl E. Klein

Summary: The proto-oncogene ALK encodes anaplastic lymphoma kinase, which is primarily expressed in the developing nervous system. Its activity is associated with learning and memory, energy expenditure, and obesity prevention. Aberrant ALK signaling causes various cancers, including being a driver in pediatric neuroblastoma. The study reveals the crystal structures of ALK's extracellular glycine-rich domain (GRD) and how it regulates receptor activity, providing insights into potential therapeutics for ALK-expressing cancers.

NATURE (2021)

Article Cell Biology

ROR and RYK extracellular region structures suggest that receptor tyrosine kinases have distinct WNT-recognition modes

Fumin Shi, Jeannine M. Mendrola, Joshua B. Sheetz, Neo Wu, Anselm Sommer, Kelsey F. Speer, Jasprina N. Noordermeer, Zhong-Yuan Kan, Kay Perry, S. Walter Englander, Steven E. Stayrook, Lee G. Fradkin, Mark A. Lemmon

Summary: WNTs play crucial roles in development and disease by signaling through various receptors, including Frizzled (FZD) and co-receptors like ROR and RYK. Crystal structures of Drosophila ROR and RYK orthologs Nrk and Derailed-2 reveal their binding characteristics with WNTs through specific domains, providing insight into how WNTs recruit co-receptors into signaling complexes.

CELL REPORTS (2021)

Review Biochemistry & Molecular Biology

Looking lively: emerging principles of pseudokinase signaling

Joshua B. Sheetz, Mark A. Lemmon

Summary: Progress has been made in understanding the role of pseudokinases in biology and disease over the past decade. Despite lacking key catalytic residues, pseudokinases show striking similarity to their kinase relatives. Recent structural data suggest that both pseudokinases and bona fide kinases maintain distinct conformational states, which play a crucial role in their function. Understanding and targeting the conformational toggle in pseudokinases could have implications for disease treatment.

TRENDS IN BIOCHEMICAL SCIENCES (2022)

Article Multidisciplinary Sciences

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations

Iris K. van Alderwerelt van Rosenburgh, David M. Lu, Michael J. Grant, Steven E. Stayrook, Manali Phadke, Zenta Walther, Sarah B. Goldberg, Katerina Politi, Mark A. Lemmon, Kumar D. Ashtekar, Yuko Tsutsui

Summary: This study investigates the molecular basis for the varying response of non-small cell lung cancers driven by EGFR mutations to tyrosine kinase inhibitors. The researchers identify structural features that contribute to inhibitor sensitivity and propose a classification system for predicting clinical outcomes.

NATURE COMMUNICATIONS (2022)

No Data Available